Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary Syndrome

Launched by KOREA UNIVERSITY ANAM HOSPITAL · Jan 19, 2021

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called evolocumab, which helps lower cholesterol levels, in patients who have recently experienced acute coronary syndrome (a serious heart condition). The goal is to see how this treatment affects the Lipid Core Burden Index, which measures the amount of harmful fat in heart plaques that could lead to heart problems. Researchers will track participants for 12 months to compare the rates of heart-related events before and after starting the cholesterol therapy.

To be eligible for this trial, participants need to be over 19 years old, have had a specific type of heart procedure called coronary stent surgery, and still have high LDL cholesterol levels (bad cholesterol) despite taking maximum doses of other cholesterol-lowering medications. Participants will receive close medical follow-up and will need to agree to the study terms. It's important to know that certain people, such as those with specific drug allergies or pregnant women, cannot participate in this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Over 19 years old
• • 2. Patients who agree to the study plan and clinical follow-up plan, voluntarily decide to participate in this study, and consent in writing to the consent to use information
• • 3. Patients who underwent NIRS-IVUS guided coronary stent surgery for acute coronary syndrome
• • 4. Patients who did not meet the LDL-Cholesterol level (\<70mg/dL) even after receiving the maximum dose of combined cholesterol therapy for 2 months
• Exclusion Criteria:
• • 1. Subjects with known hypersensitivity or contraindications to the following drugs or substances: heparin, aspirin, clopidogrel, ticagrelor, prasugrel, rosuvastatin, ezetimibe, evolocumab, lansoprazole, cobalt chromium, stainless steel nickel And contrast agents (however, even a subject who is hypersensitive to contrast agents can register if they can be controlled by steroids and pheniramine, except for known anaphylaxis.)
• • 2. Pregnant women, lactating women, or women of childbearing age who plan to become pregnant during this study
• • 3. Subjects who plan to have surgery to stop antiplatelet drugs within 12 months from registration
• • 4. Those whose surviving life is expected to be less than 1 year
• • 5. Subjects who visited the hospital due to psychogenic shock and are predicted to have low survival probability based on medical judgment
• • 6. Subjects participating in a randomized study on cholesterol therapy